Loading...
Market
What will be the primary focus of Oxford Nanopore's UK Government partnership by November 2025?
2
Oxford Nanopore Technologies•UK Government•Genomics England•UK Biobank•NHS England•Oxford Nanopore•UK
Resolution / Starting Odds
Patient Care Improvement • 25%
Biomedical Research • 25%
Pandemic Preparedness • 25%
Other • 25%
Official reports or announcements detailing the partnership's focus areas
Story
Oxford Nanopore Partners with UK Government to Enhance Genomics-Driven Healthcare for 7,000 Samples in 6 Hours
Nov 5, 2024, 07:02 AM
Oxford Nanopore Technologies has announced a partnership with the UK Government, Genomics England, UK Biobank, and NHS England to enhance genomics-driven healthcare. This initiative aims to improve patient care, support biomedical research, and bolster pandemic preparedness through advanced genomic testing. The collaboration will also focus on rapid testing for severe respiratory infections, enabling healthcare providers to match patients with appropriate treatments within six hours. Additionally, researchers have utilized Oxford Nanopore's sequencing technology to analyze methylation profiles from 7,000 samples, uncovering novel structural variants at a population scale. This partnership signifies a major step forward in the application of next-generation sequencing technology in the UK healthcare system.
View original story
Similar markets
Focus on influenza • 25%
Focus on coronaviruses • 25%
Focus on a broad range of pathogens • 25%
Other • 25%
Cancer Research • 25%
Neurological Disorders • 25%
Genetic Disorders • 25%
Other • 25%
Platform Transparency • 25%
AI Impact Mitigation • 25%
Cross-Border Cooperation • 25%
Other • 25%
Cyber defense for critical infrastructure • 25%
Development of AI threat detection tools • 25%
Collaboration with NATO on AI security • 25%
Other • 25%
Financial tracking • 25%
Border patrols • 25%
Intelligence gathering • 25%
Arrest operations • 25%
Chip Design • 25%
Manufacturing Processes • 25%
Material Science • 25%
Other • 25%
Yes • 50%
No • 50%
Influenza • 25%
Cancer • 25%
HIV • 25%
Other • 25%
Genetic Testing • 25%
Health and Wellness • 25%
Data Licensing • 25%
Other • 25%
Treatment of A. baumannii infections • 25%
Treatment of other bacterial infections • 25%
Pandemic preparedness • 25%
Other • 25%